Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stephanie Royer‐Joo
Observed names:
S Royer-Joo,
S. Royer-Joo,
Stephanie Royer-Joo
Institution:
Genentech
Observed institutions:
University of Miami,
Genentech,
Sarah Cannon,
Annexon Biosciences (United States),
University of Kansas Medical Center,
University of Colorado Cancer Center,
Sylvester Comprehensive Cancer Center,
Instacart (United States)
show all 8
ORCID:
0000-0003-4205-9927
Observed ORCID:
0000-0003-4205-9927
OpenAlex ID:
A5075304075
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
2023
·
Adrian Sacher
, Patricia LoRusso
, et al.
·
New England Journal of Medicine
·
375
PDF
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
2018
·
Asha Nayak-Kapoor
, Zhonglin Hao
, et al.
·
Journal for ImmunoTherapy of Cancer
·
171
PDF
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
2023
·
Jayesh Desai
, Guzman Alonso
, et al.
·
Nature Medicine
·
156
PDF
A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
2013
·
Zev A. Wainberg
, Wells A. Messersmith
, et al.
·
Clinical Colorectal Cancer
·
70
Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
2019
·
David E. Gerber
, Jeffrey R. Infante
, et al.
·
Clinical Cancer Research
·
63
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
2021
·
Joyce Liu
, Howard Burris
, et al.
·
Gynecologic Oncology
·
62
PDF
Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
2012
·
Caio M. Rocha Lima
, Soley Bayraktar
, et al.
·
Cancer Investigation
·
49
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
2016
·
Antonio Jimeno
, Jean‐Pascal Machiels
, et al.
·
Cancer
·
46
PDF
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer
2024
·
Komal L. Jhaveri
, Melissa K. Accordino
, et al.
·
Journal of Clinical Oncology
·
45
Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
2025
·
Adrian G. Sacher
, Wilson H. Miller
, et al.
·
Journal of Clinical Oncology
·
39
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
2020
·
Kathleen N. Moore
, Michael J. Birrer
, et al.
·
Gynecologic Oncology
·
35
PDF
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
2016
·
Anthony W. Tolcher
, Johanna C. Bendell
, et al.
·
Clinical Cancer Research
·
34
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
2024
·
Yoonha Choi
, Neekesh V. Dharia
, et al.
·
Clinical Cancer Research
·
29
Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors
2020
·
Dejan Juric
, Kevin Kalinsky
, et al.
·
Cancer Research
·
23
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
2019
·
Shuguang Ma
, Julia Suchomel
, et al.
·
British Journal of Clinical Pharmacology
·
22
PDF
346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors
2015
·
A. Nayak
, Z. Hao
, et al.
·
European Journal of Cancer
·
19
Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.
2013
·
Anthony W. Tolcher
, Kyriakos P. Papadopoulos
, et al.
·
Journal of Clinical Oncology
·
18
Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).
2012
·
Saifuddin M. Kasubhai
, Johanna C. Bendell
, et al.
·
Journal of Clinical Oncology
·
18
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
2025
·
Philippe L. Bedard
, Komal L. Jhaveri
, et al.
·
European Journal of Cancer
·
15
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).
2022
·
Philippe L. Bedard
, Melissa Kate Accordino
, et al.
·
Journal of Clinical Oncology
·
15
Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS
2008
·
J. Polikoff
, J. D. Hainsworth
, et al.
·
Journal of Clinical Oncology
·
15
Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).
2011
·
A. D. Baron
, C. L. O'Bryant
, et al.
·
Journal of Clinical Oncology
·
13
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
2025
·
V. Gambardella
, M.K. Accordino
, et al.
·
ESMO Open
·
11
PDF
Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
2023
·
Jayesh Desai
, Sae-Won Han
, et al.
·
Cancer Research
·
11
Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer
2020
·
Komal Jhaveri
, Kevin Kalinsky
, et al.
·
Cancer Research
·
11
Show more works
View as search
Works count:
83
Citation count:
1,467
H-index:
18
I10-index:
28
Year
Topic
Type